Cytosorbents Overview
DCF fair value estimate for Cytosorbents: $2.4.
Get informed when a big investor buys or sells
+ Follow$2.35
Overvalued by 42.0% based on the discounted cash flow analysis.
Cytosorbents (CTSO) currently reports a DCF fair value of $2.4. Use the charts on this page to explore Cytosorbents's DCF fair value history and peer comparisons.
Cytosorbents's discounted cash flow (DCF) fair value estimate is $2.4, about 42.0% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $2.4, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cytosorbents, and consider following CTSO for alerts when major investors trade the stock.
Cytosorbents is classified in the Healthcare sector. On DCF fair value, it currently shows $2.4. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTSO with unrelated industries.
